Author + information
- Fleur Tjong,
- Tom Brouwer,
- Brendan Koop,
- Brian Soltis,
- Allan Shuros,
- Martin Burke and
- Reinoud Knops
Background: Conventional pacemakers and implantable cardioverter defibrillators (ICD) have high rates of lead complications. We examine the next step in modular leadless cardiac rhythm management: chronic performance of an anti-tachycardia (ATP) leadless cardiac pacemaker (LCP), commanded by a subcutaneous ICD (S-ICD) through wireless, intra-body, device-device communication.
Methods: The modular system of an ATP-enabled LCP and S-ICD prototypes (both Boston Scientific) was evaluated in three animal models (ovine, canine, swine) both in acute and chronic experiments. LCP performance & ATP delivery, S-ICD to LCP communication, and S-ICD and LCP rhythm discrimination were assessed.
Results: The LCP and S-ICD were successfully implanted in all animals (n=39). Twenty three animals are being evaluated for chronic performance, reported through a median follow-up of 75 days. Echocardiography at implant, showed no pericardial effusion, dislodgement or valve interaction. Chronic LCP electrical performance at 30 days (n=16) was: mean pacing threshold 0.60±0.30V, mean impedance 835±113Ω. Uni-directional communication from the S-ICD to the LCP was successful in 99% (n=306/309) resulting in 100% successful ATP delivery by the LCP. Adequate S-ICD sensing was observed during normal sinus rhythm, LCP pacing, and VT/VF.
Conclusions: We demonstrated appropriate chronic VVI functionality, wireless device-device communication and ATP-delivery by the LCP in a combined modular therapy system (LCP and S-ICD).
Room 146 A
Saturday, March 18, 2017, 8:51 a.m.-9:01 a.m.
Session Title: Highlighted Original Research: Arrhythmias and Clinical EP and the Year in Review
Abstract Category: 5. Arrhythmias and Clinical EP: Devices
Presentation Number: 901-10
- 2017 American College of Cardiology Foundation